The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell–based immunotherapy

Abstract

Key Points• Direct analysis of the HLApresented peptidome identifies a distinct antigenic signature in MM.• T-cell responses for these antigens are detectable exclusively in MM patients and can be induced in vitro in response-naive patients.Direct analysis of HLA-presented antigens by mass spectrometry provides a comprehensive view on the antigenic landscape of different tissues/malignancies and enables the identification of novel, pathophysiologically relevant T-cell epitopes. Here, we present a systematic and comparative study of the HLA class I and II presented, nonmutant antigenome of multiple myeloma (MM). Quantification of HLA surface expression revealed elevated HLA molecule counts on malignant plasma cells compared with normal B cells, excluding relevant HLA downregulation in MM. Analyzing the presentation of established myeloma-associated T-cell antigens on the HLA ligandome level, we found a substantial proportion of antigens to be only infrequently presented on primary myelomas or to display suboptimal degrees of myeloma specificity. However, unsupervised analysis of our extensive HLA ligand data set delineated a panel of 58 highly specific myeloma-associated antigens (including multiple myeloma SET domain containing protein) which are characterized by frequent and exclusive presentation on myeloma samples. Functional characterization of these target antigens revealed peptide-specific, preexisting CD8 1 T-cell responses exclusively in myeloma patients, which is indicative of pathophysiological relevance.Furthermore, in vitro priming experiments revealed that peptide-specific T-cell responses can be induced in response-naive myeloma patients. Together, our results serve to guide antigen selection for T-cell-based immunotherapy of MM. (Blood. 2015;126(10):1203-1213

Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design

“…On the other hand, the lower expression of HLA class II molecules compared to HLA class I on RCC cells and healthy monocytes might be the reason for this disparity. 46,51 Since RCC tissue is often infiltrated by lymphocytes, 52 we compared antigens found on PBMCs with tissue samples and determined that over three-quarters of these antigens were overlapping for HLA class I. Subtracting PBMC-derived peptides from results of tissue analysis allowed for a focused analysis of kidney-associated antigens in malignant versus normal kidney tissue.…”

A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma

“…25,[43][44][45][46] Here, we profiled epitope recognition in a cohort of 18 patients after allogeneic or autologous HSCT or novel agent therapy, revealing strikingly disease-specific and overlapping patterns of epitope reactivity. All of these patients showed oligoclonal serum antibodies on immunofixation, suggesting ongoing B-cell immune responses.…”

“…They are either encoded by the tumor mutanome, harbor tumor-specific posttranslational modifications, or are simply part of tightly regulated or immunologically inaccessible antigens reexpressed in the tumor. [23][24][25][26] For accessibility reasons the myeloma cell surface represents an important source for therapeutically relevant tumor epitopes. However, identification of potentially targetable epitopes may be cumbersome because they may not easily be detected by gene expression profiling or genome sequencing as these methodologies do not allow for prediction of their posttranslational modifications or surface exposure.…”

Encouraging Debut of Immunotherapy In Myeloma

“…However, it is associated with high morbidity and mortality and remains an option for only a fraction of patients [2].…”